Filaggrin expression via immunohistochemistry in basal cell carcinoma and squamous cell carcinoma.
Aged
Carcinoma, Basal Cell
/ diagnosis
Carcinoma, Squamous Cell
/ diagnosis
Cell Differentiation
/ genetics
Dermatitis, Atopic
/ epidemiology
Epidermis
/ metabolism
Female
Filaggrin Proteins
Genetic Predisposition to Disease
Humans
Ichthyosis Vulgaris
/ epidemiology
Immunohistochemistry
/ methods
Intermediate Filament Proteins
/ genetics
Loss of Function Mutation
/ genetics
Male
Skin Neoplasms
/ pathology
Staining and Labeling
/ methods
Tissue Array Analysis
/ methods
atopic dermatitis
basal cell carcinoma
filaggrin
ichthyosis vulgaris
squamous cell carcinoma
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
20
01
2021
received:
30
06
2020
accepted:
26
01
2021
pubmed:
6
2
2021
medline:
27
11
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Filaggrin is a protein integral to the structure and function of the epidermis. Filaggrin (FLG) loss-of-function (LOF) mutations are common and increase the risk of developing atopic dermatitis (AD) and ichthyosis vulgaris (IV). Epidemiologic data suggest a link between skin cancer and AD. We examined if FLG staining pattern can be used to characterize cutaneous squamous cell carcinomas (SCC), basal cell carcinomas (BCC), and reactive squamous epithelium. Tissue microarrays (TMAs) were created from 196 cases of formalin-fixed paraffin-embedded (FFPE) SCC and 144 BCC cases. TMAs and sections of reactive squamous epithelium were stained with optimized anti-FLG antibody and evaluated for FLG expression (normal, abnormal, or negative). FLG was absent in poorly differentiated (PD) compared to well-differentiated (WD) SCC (P < .0001) and moderately-differentiated (MD) (P = .0231) SCC, and in MD compared to WD SCC (P = .0099). Abnormal staining was significantly increased in PD compared to WD cases (P = .0039) and in MD compared to WD cases (P = .0006). Most BCC did not exhibit FLG expression (P < .05). Reactive squamous epithelium demonstrated normal, but exaggerated FLG expression. Our findings demonstrate the differences in FLG expression patterns in types of keratinocyte carcinomas and their mimickers.
Sections du résumé
BACKGROUND
BACKGROUND
Filaggrin is a protein integral to the structure and function of the epidermis. Filaggrin (FLG) loss-of-function (LOF) mutations are common and increase the risk of developing atopic dermatitis (AD) and ichthyosis vulgaris (IV). Epidemiologic data suggest a link between skin cancer and AD. We examined if FLG staining pattern can be used to characterize cutaneous squamous cell carcinomas (SCC), basal cell carcinomas (BCC), and reactive squamous epithelium.
METHODS
METHODS
Tissue microarrays (TMAs) were created from 196 cases of formalin-fixed paraffin-embedded (FFPE) SCC and 144 BCC cases. TMAs and sections of reactive squamous epithelium were stained with optimized anti-FLG antibody and evaluated for FLG expression (normal, abnormal, or negative).
RESULTS
RESULTS
FLG was absent in poorly differentiated (PD) compared to well-differentiated (WD) SCC (P < .0001) and moderately-differentiated (MD) (P = .0231) SCC, and in MD compared to WD SCC (P = .0099). Abnormal staining was significantly increased in PD compared to WD cases (P = .0039) and in MD compared to WD cases (P = .0006). Most BCC did not exhibit FLG expression (P < .05). Reactive squamous epithelium demonstrated normal, but exaggerated FLG expression.
CONCLUSIONS
CONCLUSIONS
Our findings demonstrate the differences in FLG expression patterns in types of keratinocyte carcinomas and their mimickers.
Substances chimiques
FLG protein, human
0
Filaggrin Proteins
0
Intermediate Filament Proteins
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
877-883Subventions
Organisme : Innovation Fund
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Mildner M, Jin J, Eckhart L, et al. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. J Invest Dermatol. 2010;130(9):2286-2294.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
Nomura T, Sandilands A, Akiyama M, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007;119(2):434-440.
Zenisek A, Kral JA, Hais IM. Sun-screening effect of urocanic acid. Biochim Biophys Acta. 1955;18(4):589-591.
Skaaby T, Husemoen LL, Jorgensen T, et al. Associations of filaggrin gene loss-of-function variants and human papillomavirus-related cancer and pre-cancer in Danish adults. PloS One. 2014;9(6):e99437. https://dx.doi.org/10.1371/journal.pone.0099437.
Andersen YM, Egeberg A, Balslev E, et al. Filaggrin loss-of-function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross-sectional studies. J Eur Acad Dermatol Venereol. 2017;31(6):1038-1043.
Kaae J, Thyssen JP, Johansen JD, et al. Filaggrin gene mutations and risk of basal cell carcinoma. Br J Dermatol. 2013;169(5):1162-1164.
Klein-Szanto AJ, Barr RJ, Reiners JJ Jr, Mamrack MD. Filaggrin distribution in keratoacanthomas and squamous cell carcinoma. Arch Pathol Lab Med. 1984;108(11):888-890.
Kaae J, Szecsi PB, Meldgaard M, et al. Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma. Br J Dermatol. 2014;170(6):1380-1381.
Tan KB, Tan SH, Aw DC, et al. Simulators of squamous cell carcinoma of the skin: diagnostic challenges on small biopsies and clinicopathological correlation. J Skin Cancer. 2013;2013:752864. https://dx.doi.org/10.1155/2013/752864.
Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer. 2011;2011:210813. https://dx.doi.org/10.1155/2011/210813.
Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 2008;18(2):89-97.
Anagnostou VK, Lowery FJ, Syrigos KN, Cagle PT, Rimm DL. Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? Arch Pathol Lab Med. 2010;134(4):613-619.
Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360-363.
Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327.
Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 2011;127(3):661-667.
Furuta T, Okamiya K, Shibasaki H, Kasuya Y. Pharmacokinetics of stable isotopically labeled L-histidine in humans and the assessment of in vivo histidine ammonia lyase activities. Drug Metab Dispos. 1996;24(1):49-54.
Denecker G, Hoste E, Gilbert B, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol. 2007;9(6):666-674.
Hoste E, Kemperman P, Devos M, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233-2241.
Kim Y, He YY. Ultraviolet radiation-induced non-melanoma skin cancer: regulation of DNA damage repair and inflammation. Genes Dis. 2014;1(2):188-198.
D'Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci. 2013;14(6):12222-12248.
Tajima T, Ibe M, Matsushita T, Kamide R. A variety of skin responses to ultraviolet irradiation in patients with atopic dermatitis. J Dermatol Sci. 1998;17(2):101-107.
Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B. 2001;64(2-3):93-98.
ten Berge O, van Weelden H, Bruijnzeel-Koomen CA, de Bruin-Weller MS, Sigurdsson V. Throwing a light on photosensitivity in atopic dermatitis: a retrospective study. Am J Clin Dermatol. 2009;10(2):119-123.
Hagstromer L, Ye W, Nyren O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123-1127.
Jensen AO, Svaerke C, Kormendine Farkas D, Olesen AB, Kragballe K, Sorensen HT. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977-2006). Am J Clin Dermatol. 2012;13(1):29-36.
Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019;156(2):158-171.
Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086-1097.
Cho JM, Davis DMR, Wetter DA, Bartley AC, Brewer JD. Association between atopic dermatitis and squamous cell carcinoma: a case-control study. Int J Dermatol. 2018;57(3):313-316.
Synnerstad I, Fredrikson M, Ternesten-Bratel A, Rosdahl I. Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(12):1423-1428.
Sample A, He YY. Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed. 2018;34(1):13-24.
Brown SJ, Kroboth K, Sandilands A, et al. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. J Invest Dermatol. 2012;132(1):98-104.
Pearton DJ, Dale BA, Presland RB. Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. J Invest Dermatol. 2002;119(3):661-669.